Do you have metastatic breast cancer?

Veronica: A phase II, multicenter, randomised study to compare the efficacy of venetoclax plus fulvestrant

This research project is testing a new treatment for locally advanced or metastatic ER-positive breast cancer. The new treatment is called venetoclax given in combination with fulvestrant and we we want to know whether adding venetoclax will add to the effectiveness of the fulvestrant. 

Fulvestrant is a drug that is designed to bind to the oestrogen receptors, completely blocking the ability of oestrogen to attach to these receptors. This can help to slow down the growth of ER-positive breast cancer.

Venetoclax has been approved for treatment of a type of leukaemia. In this study, venetoclax is an experimental drug, which means health authorties have not approved it in combination with fulvestrant for the treatment of ER-positive breast cancer.

Anticipated date that enrolment will close: Late 2019

Who can take part

  • People with oestregen receptor (ER-positive) locally advanced or metastatic breast cancer

  • Metastatic disease measurable on scan

  • No more than 2 previous types of hormone therapy for metastatic disease

  • Previous treatment with Palbociclib or another CDK4/6 inhibitor

  • Previous treatment with fulvestrant is an exclusion

What is involved for you

  • Screening (to see if this research project is suitable for you)
    • Blood, Pregnancy and Hepatitis tests
    • Urine sample
    • CT or MRI or X-ray (to assess tumour)
    • Provide tissue sample of tumour
  • Treatment and follow-up (if eligible)
    • Injections and/or tablet
    • In cycle 1, you will have several visits
    • After cycle 1, one visit every 4 weeks
    • Urine samples, blood tests, general health information
check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
PMCC 18.137 / MH HREC 2018.137
Breast Trials Team
03 8559 7140